Cancer immunotherapy has undoubtedly expanded the cancer treatment landscape and improved patient outlook, which can in part be attributed to the recognition of the importance of the cancer-immunity cycle as a whole. In this blog, we provide an overview of the cancer-immunity cycle and highlight some preclinical models that can facilitate cancer immunotherapy research.
Cancer biomarkers that do not cross the translational gap to clinical practice can still further research and drug discovery. In this article, we review several techniques commonly used for cancer biomarker imaging at preclinical stages, as well as recent technological advances.
Triple-negative breast cancer is particularly aggressive, challenging to treat, and accounts for 15-20% of all breast cancers. In this blog, we review a study published in Nature Communications that examines the transforming growth factor-β targetable signaling pathway, its role in malignant cancer progression and immune suppression, and tumor-derived extracellular vesicles as diagnostic and prognostic biomarkers.
The combination of anti-cancer drugs, or combination therapy, has been hailed as a “cornerstone of cancer therapy” since it targets key pathways synergistically, thereby enhancing efficacy compared to monotherapies. This blog takes a look at a recent publication in Nature, which reported the effects of 2025 pairwise drug combinations in breast, colon, and pancreatic cell lines.